Foray Pharma Distributors Profile
Key Indicators
- Authorised Capital ₹ 6.10 M
- Paid Up Capital ₹ 6.10 M
- Company Age 10 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.50 Cr
- Revenue Growth -5.30%
- Profit Growth
- Ebitda 3.86%
- Net Worth 13.74%
- Total Assets 3.23%
About Foray Pharma Distributors
Foray Pharma Distributors Private Limited (FPDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 18 November 2014 and has a history of Ten years and three months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.10 M and a paid-up capital of Rs 6.10 M.
The company has closed loans amounting to ₹1.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Hitesh Shah, Hardik Shah, and Prashim Masalia serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52100MH2014PTC259458
- Company No.
259458
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Nov 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Foray Pharma Distributors?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hitesh Shah  | Director | 30-Sep-2019 | Current |
| Hardik Shah | Director | 19-Dec-2018 | Current |
| Prashim Masalia | Director | 19-Dec-2018 | Current |
Financial Performance of Foray Pharma Distributors.
Foray Pharma Distributors Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.3% decrease. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 13.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Foray Pharma Distributors?
In 2023, Foray Pharma Distributors had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹15.00 M
Charges Breakdown by Lending Institutions
- The Shamrao Vithal Co-Operative Bank Limited : 1.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Jan 2015 | The Shamrao Vithal Co-Operative Bank Limited | ₹1.50 Cr | Satisfied |
How Many Employees Work at Foray Pharma Distributors?
Unlock and access historical data on people associated with Foray Pharma Distributors, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Foray Pharma Distributors, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Foray Pharma Distributors's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
